logo
Twitter
Discord
Email
logo
ADC Therapeutics SA

ADC Therapeutics SA

NYSE•ADCT
CEO: Dr. Ameet Mallik M.B.A., M.S.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-05-18
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Contact Information
BiopOle, Route de la Corniche 3B, Epalinges, 1066, Switzerland
41-21-653-02-00
www.adctherapeutics.com
Market Cap
$447.20M
P/E (TTM)
-3.0
5.6
Dividend Yield
--
52W High
$4.80
52W Low
$1.05
52W Range
68%
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q3 2025 Data

Revenue

$16.43M-11.03%
4-Quarter Trend

EPS

-$0.30-28.57%
4-Quarter Trend

FCF

-$29.63M+17.30%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Nine months total revenue reached $58.30M, showing 8.1% growth, significantly boosted by $6.03M license revenue increase.
Net Loss Widens Nine months net loss totaled $(136.21M), worsening by 7.2% primarily due to $13.47M in restructuring and impairment charges.
Strong Cash Position Cash and equivalents totaled $234.74M as of September 30, 2025, supporting operations for at least twelve months.
Financing Secured June 2025 Private Placement provided $93.1M net proceeds, supplemented by October 2025 placement proceeds post-period.

Risk Factors

Restructuring Asset Impairment Recognized $13.47M restructuring costs, including $7.24M impairment loss on long-lived assets related to UK facility closure.
Continued Capital Needs Expectation to continue incurring substantial net losses, necessitating raising additional capital under uncertain market conditions.
Trade Policy Uncertainty Potential US tariffs could increase cost of sales and operating expenses, adversely affecting financial condition.
Drug Pricing Policy Risk New US administration drug pricing policies, like MFN, could substantially reduce ZYNLONTA list price revenues.

Outlook

LOTIS-5 Data Timeline Expect topline progression-free survival data from LOTIS-5 confirmatory Phase 3 trial in the first half of 2026.
PSMA ADC Advancement Continue IND-enabling activities for next-generation PSMA-targeting ADC asset, expecting wind-down of related costs by end of 2025.
Future Financing Strategy Plan to fund operating needs through existing cash, ZYNLONTA revenue, and exploring strategic collaborations or debt financings.
LOTIS-7 Data Update Plan to share more mature LOTIS-7 trial data via corporate update by year-end, followed by FDA engagement.

Peer Comparison

Revenue (TTM)

ADC Therapeutics SAADCT
$75.21M
+6.4%
Autolus Therapeutics plcAUTL
$51.13M
+330.9%
Rocket Pharmaceuticals, Inc.RCKT
$9.19M
-10.9%

Gross Margin (Latest Quarter)

ADC Therapeutics SAADCT
92.7%
-2.7pp
Quantum-Si incorporatedQSI
35.1%
-11.5pp
Solid Biosciences Inc.SLDB
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ENGN$623.04M-9.5-31.1%14.4%
DBVT$587.04M-3.9-295.2%0.0%
FULC$581.70M-9.5-32.2%3.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.0%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 26, 2026
|
EPS:-$0.32
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $16.43M-11.0%
    |
    EPS: $-0.30-28.6%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $18.84M+8.2%
    |
    EPS: $-0.50+31.6%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $23.03M+27.6%
    |
    EPS: $-0.36-35.7%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 27, 2025|
    Revenue: $70.84M+1.8%
    |
    EPS: $-1.62+44.9%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $18.46M+27.4%
    |
    EPS: $-0.42-27.6%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $17.41M-9.7%
    |
    EPS: $-0.38-34.5%
    Meet
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 6, 2024|
    Revenue: $18.05M-4.9%
    |
    EPS: $-0.56-24.3%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 13, 2024|
    Revenue: $69.56M-66.9%
    |
    EPS: $-2.94-47.7%
    Miss